Analgesic Effects and Skin Sensitization of 1% Topical Cannabidiol Oil for Myofascial Pain
Article Sidebar
Main Article Content
Abstract
OBJECTIVES: To evaluate the analgesic effects and skin sensitization of 1% topical cannabidiol (CBD) oil in participants with myofascial pain.
MATERIALS AND METHODS: This study included 192 participants diagnosed with myofascial pain. Participants applied 1 g of 1% topical CBD oil to the painful area twice daily for 14 days. Pain intensity was assessed using the Numerical Rating Scale (NRS) at baseline and at 30, 60, and 120 minutes and on Days 7 and 14. Analgesic effects were determined by changes in pain scores and percentage of pain relief. Skin sensitization was evaluated using a human patch test consisting of induction and challenge phases, with assessment of local cutaneous reactions.
RESULTS: Among 192 participants, 78 (40.6%) were male and 114 (59.4%) were female. The shoulder was the most frequently reported pain location (32.8%), followed by the leg (29.7%) and back (22.9%). Mean pain scores progressively decreased following treatment, with significant reductions from baseline at all assessment time points (p < 0.001). Pain relief increased progressively throughout the 14-day treatment period, reaching approximately 41% on Day 14. No clinically significant cutaneous reactions or evidence of skin sensitization were observed during the human patch test.
CONCLUSION: The findings suggest that 1% topical CBD oil may reduce pain intensity in individuals with myofascial pain and was well tolerated without observable skin sensitization. Further randomized controlled studies are warranted to confirm its efficacy and long-term safety.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Yap EC. Myofascial pain: an overview. Ann Acad Med Singap. 2007;36(1):43-8.
Steen JP, Jaiswal KS, Kumbhare D. Myofascial pain syndrome: an update on clinical characteristics, etiopathogenesis, diagnosis, and treatment. Muscle Nerve. 2025;71(5):889-910. doi: 10.1002/mus.28377.
Peng J, Fan M, An C, et al. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic Clin Pharmacol Toxicol. 2022;130(4):439-56. doi: 10.1111/bcpt.13710.
Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacology. 2022;107(3-4):131-49. doi: 10.1159/000521683.
Porter B, Marie BS, Milavetz G, et al. Cannabidiol (CBD) use by older adults for acute and chronic pain. J Gerontol Nurs. 2021;47(7):6-15. doi: 10.3928/00989134-20210610-02.
Walczyńska-Dragon K, Kurek-Górecka A, Fiegler-Rudol J, et al. The therapeutic potential of cannabidiol in the management of temporomandibular disorders and orofacial pain. Pharmaceutics. 2025;17(3):328. doi: 10.3390/pharmaceutics17030328.
Nitecka-Buchta A, Nowak-Wachol A, Wachol K, et al. Myorelaxant effect of transdermal cannabidiol application in patients with TMD: a randomized, double-blind trial. J Clin Med. 2019;8(11):1886. doi: 10.3390/jcm8111886.
Xu DH, Cullen BD, Tang M, et al. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2020;21(5):390-402. doi: 10.2174/1389201020666191202111534.
Heineman JT, Forster GL, Stephens KL, et al. A randomized controlled trial of topical cannabidiol for the treatment of thumb basal joint arthritis. J Hand Surg Am. 2022;47(7):611- 20. doi: 10.1016/j.jhsa.2022.03.002.
Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2021;238(1):9-28. doi: 10.1007/s00213-020-05712-8.
Mlost J, Bryk M, Starowicz K. Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci. 2020;21(22):8870. doi: 10.3390/ijms21228870.
Scholfield CN, Waranuch N, Kongkaew C. Systematic review on transdermal/topical cannabidiol trials: a reconsidered way forward. Cannabis Cannabinoid Res. 2023;8(4):589-602. doi: 10.1089/can.2021.0154.
Umpreecha C, Bhalang K, Charnvanich D, et al. Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial. BMC Complement Med Ther. 2023;23(1):57. doi: 10.1186/s12906-023-03886-0.
Cásedas G, Yarza-Sancho M, López V. Cannabidiol (CBD): a systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals (Basel). 2024;17(11):1438. doi: 10.3390/ph17111438.
